000300741 001__ 300741
000300741 005__ 20250502112933.0
000300741 0247_ $$2doi$$a10.21873/anticanres.17577
000300741 0247_ $$2pmid$$apmid:40295057
000300741 0247_ $$2ISSN$$a0250-7005
000300741 0247_ $$2ISSN$$a1791-7530
000300741 037__ $$aDKFZ-2025-00901
000300741 041__ $$aEnglish
000300741 082__ $$a610
000300741 1001_ $$0P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aZwicker, Felix$$b0$$eFirst author$$udkfz
000300741 245__ $$aLong-term Outcomes of Helical Tomotherapy in Lymph Node-positive Breast Cancer Following Breast-conserving Surgery.
000300741 260__ $$aKapandriti, Attiki, Greece$$bInternational Institute of Anticancer Research$$c2025
000300741 3367_ $$2DRIVER$$aarticle
000300741 3367_ $$2DataCite$$aOutput Types/Journal article
000300741 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1746175972_32
000300741 3367_ $$2BibTeX$$aARTICLE
000300741 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300741 3367_ $$00$$2EndNote$$aJournal Article
000300741 500__ $$a#EA:E055#
000300741 520__ $$aAdjuvant radiotherapy is an integral component of the interdisciplinary curative treatment of lymph node-positive breast cancer. We investigated long-term clinical outcomes of helical tomotherapy following breast-conserving surgery.This single-center analysis included 80 female patients with breast cancer stages T1-T4 and lymph node metastasis (N1-N3) who underwent breast-conserving surgery, sentinel node biopsy, and/or axillary lymph node dissection. Patients received adjuvant fractionated radiation therapy to the whole breast and regional lymph node areas using helical tomotherapy. Boost irradiation was delivered sequentially or through the simultaneous integrated boost technique. Local control (LC), metastasis, survival, toxicity, and secondary malignancy rates were retrospectively analyzed.The mean follow-up duration was 75 months. The 5- and 8-year overall survival rates were 89.4% and 87.0%, respectively. LC rates at 5- and 8-year were 98.7%, and metastasis-free survival rates were 91.2% and 85.2%, respectively. Acute erythema occurred in 70% (Grades 1-2) and 26% (Grade 3) of patients. Ipsilateral arm lymphedema of Grade 1 and Grade 2 developed in 10% and 1.3% of the treated patients, respectively. Acute or late toxicities exceeding Grade 3 were not observed.Helical tomotherapy showed excellent long-term results and low toxicity rates as adjuvant radiotherapy in patients with lymph node-positive breast cancer. The incidence of secondary malignancies was relatively low and corresponded to the preexisting records on radiation therapy. Broader clinical implementation of helical tomotherapy could benefit patients.
000300741 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000300741 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300741 650_7 $$2Other$$aHelical tomotherapy
000300741 650_7 $$2Other$$aadjuvant radiotherapy
000300741 650_7 $$2Other$$alymph node-positive breast cancer
000300741 650_2 $$2MeSH$$aHumans
000300741 650_2 $$2MeSH$$aFemale
000300741 650_2 $$2MeSH$$aBreast Neoplasms: radiotherapy
000300741 650_2 $$2MeSH$$aBreast Neoplasms: pathology
000300741 650_2 $$2MeSH$$aBreast Neoplasms: surgery
000300741 650_2 $$2MeSH$$aBreast Neoplasms: mortality
000300741 650_2 $$2MeSH$$aMiddle Aged
000300741 650_2 $$2MeSH$$aMastectomy, Segmental
000300741 650_2 $$2MeSH$$aAdult
000300741 650_2 $$2MeSH$$aAged
000300741 650_2 $$2MeSH$$aLymphatic Metastasis: radiotherapy
000300741 650_2 $$2MeSH$$aRadiotherapy, Intensity-Modulated: methods
000300741 650_2 $$2MeSH$$aRadiotherapy, Intensity-Modulated: adverse effects
000300741 650_2 $$2MeSH$$aRadiotherapy, Adjuvant: adverse effects
000300741 650_2 $$2MeSH$$aRadiotherapy, Adjuvant: methods
000300741 650_2 $$2MeSH$$aRetrospective Studies
000300741 650_2 $$2MeSH$$aTreatment Outcome
000300741 650_2 $$2MeSH$$aLymph Nodes: pathology
000300741 650_2 $$2MeSH$$aSentinel Lymph Node Biopsy
000300741 650_2 $$2MeSH$$aLymph Node Excision
000300741 7001_ $$aRaether, Luis-Philipp$$b1
000300741 7001_ $$aKlepper, Rudolf$$b2
000300741 7001_ $$0P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0$$aHauswald, Henrik$$b3$$udkfz
000300741 7001_ $$aHoefel, Sebastian$$b4
000300741 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b5$$udkfz
000300741 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b6$$udkfz
000300741 7001_ $$aSchempp, Michael$$b7
000300741 773__ $$0PERI:(DE-600)2145376-7$$a10.21873/anticanres.17577$$gVol. 45, no. 5, p. 2025 - 2040$$n5$$p2025 - 2040$$tAnticancer research$$v45$$x0250-7005$$y2025
000300741 909CO $$ooai:inrepo02.dkfz.de:300741$$pVDB
000300741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000300741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9e8fb0cffee71172acb6ac45c40bade0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000300741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000300741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000300741 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000300741 9141_ $$y2025
000300741 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANTICANCER RES : 2022$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000300741 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-10
000300741 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000300741 9200_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x0
000300741 980__ $$ajournal
000300741 980__ $$aVDB
000300741 980__ $$aI:(DE-He78)E055-20160331
000300741 980__ $$aUNRESTRICTED